Kytopen, a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; announced, a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid™ vector technology with Kytopen’s Flowfect Tx™ GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells.
Aldveron’s Nanoplasmid vector offers high transgene expression and improved safety profile while the Flowfect® continuous flow technology ensures gentle gene delivery with unlimited scale. Together these technologies provide an enhanced CRISPR-mediated T-cell engineering workflow resulting in high yields saving cell therapy developers time in a cost-effective manner.
The two companies created a joint poster of the resulting data that Kytopen will present at the International Society of Cell & Gene Therapy (“ISCT”) Annual Meeting, May 7-10, 2025, in New Orleans, LA, highlighting the increase in the overall yield of final drug substance and ease of manufacturing over viral and electroporation technologies. The data will also be featured in Kytopen’s Global Showcase Oral Presentation on Thursday, May 8.
Also Read: Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
“The work with Aldevron is part of a larger, shared commitment to enable advance cell therapies by streamlining workflows to deliver greater yields of healthier cells,” said Kevin Gutshall, Chief Commercial Officer at Kytopen. “The combination of our technologies provides a GMP process for delivering high-quality CAR-T cells that is now available for use in clinical and commercial applications.”
“This collaboration continues to demonstrate the superior performance of our Nanoplasmid vectors across novel transfection technologies,” said Anu Codaty, VP of Global Marketing and Strategy for Aldevron. “The combination of the Nanoplasmid technology with Kytopen‘s Flowfect® cell engineering technology has delivered higher edited-cell yields faster, which will help meet the growing patient demand as the adoption of CRISPR-based therapies accelerates.”
SOURCE: PRNewswire